Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Denosumab Global Safety Assessment Among Women With Postmenopausal Osteoporosis (PMO), Men With Osteoporosis, and Men and Women Who Receive Prolia With Glucocorticoid Exposure in Multiple Observational Databases

NCT02520362 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02520362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02520362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Denosumab Global Safety Assessment Among Women With Postmenopausal Osteoporosis (PMO), Men With Osteoporosis, and Men and Women Who Receive Prolia With Glucocorticoid Exposure in Multiple Observational Databases
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
May 31, 2010
Completion date
July 21, 2023
Enrollment
517,991 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis